Filing Overview
The supplied filing is a Form 8-K for Coeptis Therapeutics Holdings, Inc. (formerly Bull Horn Holdings Corp.), filed November 3, 2022, reporting events occurring primarily on October 28, 2022. The request metadata identifies “Z Squared Inc.,” which does not match the registrant named in the filing.
Business Context and Reporting Period
- On October 28, 2022, Bull Horn’s wholly owned subsidiary merged with Coeptis Therapeutics, Inc., with Coeptis surviving as a wholly owned subsidiary.
- The transaction was accounted for as a reverse merger and recapitalization, with Coeptis treated as the accounting acquirer. Future historical financial statements will reflect Coeptis rather than the former shell company.
- The company changed its name to Coeptis Therapeutics Holdings, Inc. and trades on Nasdaq under COEP and COEPW.
- The filing includes audited financial statements for the years ended December 31, 2021 and 2020 and unaudited financial statements for the six months ended June 30, 2022 and comparable 2021 periods.
Financial Condition and Key Metrics
| Metric | Reported value | Comparable period or comment |
|---|---|---|
| Revenue, fiscal 2021 | $75,000 | $14,561 in fiscal 2020; primarily consulting revenue |
| Revenue, six months ended June 30, 2022 | $0 | $75,000 in the comparable 2021 period |
| Revenue, three months ended June 30, 2022 | $0 | $0 in the comparable 2021 period |
| Operating expenses, fiscal 2021 | $14.3 million | $5.9 million in fiscal 2020 |
| Operating expenses, six months ended June 30, 2022 | $25.6 million | $4.4 million in the comparable 2021 period |
| Net loss, fiscal 2021 | $13.45 million | Accumulated deficit was $27.55 million at December 31, 2021 |
| Net loss, three months ended June 30, 2022 | $9.80 million | Accumulated deficit was $56.53 million at June 30, 2022 |
| Interest expense, six months ended June 30, 2022 | $119,644 | $77,823 in the comparable 2021 period |
| Cash and cash equivalents at June 30, 2022 | $2.38 million | $2.18 million at December 31, 2021 and $202,965 at December 31, 2020 |
The filing text does not provide clear operating cash flow, free cash flow, gross margin, operating margin, or net debt values. Management expects negative operating cash flow through at least the end of 2023 or longer.
Material Changes Versus Prior Periods
- Fiscal 2021 operating expenses increased approximately 142% from 2020, primarily because of higher professional fees and directors’ and officers’ insurance costs.
- Six-month 2022 operating expenses increased approximately 481% year over year, primarily due to merger-related professional fees and warrant expense.
- General and administrative expense for the six months ended June 30, 2022 was $25.46 million, compared with $4.32 million in the comparable 2021 period; the filing attributes a substantial portion to warrant expense.
- Revenue declined to zero in the six months ended June 30, 2022 from $75,000 in the comparable 2021 period.
- The company shifted strategic focus away from previously marketed products and toward early-stage oncology, autoimmune and drug-delivery technologies.
Merger, Capitalization and Ownership
- Former Coeptis stockholders received 17,270,079 shares, while former Bull Horn stockholders retained 2,246,760 shares. Former Coeptis holders owned approximately 88% of combined voting power after closing.
- Immediately after closing, the company reported approximately 19.5 million common shares outstanding and no preferred shares outstanding.
- Warrants included warrants for 1,563,912 shares at an average exercise price of approximately $7.93, plus public and private warrants exercisable for an aggregate of 7.5 million warrants or underlying shares as described in the filing, generally at $11.50 per whole share.
- Coeptis raised $3.27 million in a Regulation A offering and received $5.25 million from warrant exercises before the merger.
- The transaction resulted in a change of control, a new seven-member board, new officers, amended organizational documents and the company’s exit from shell-company status.
Business, Outlook and Management Commentary
- The pipeline is predominantly preclinical or discovery stage. Key programs include CD38-GEAR-NK and CD38-Diagnostic through VyGen-Bio, and a SNAP-CAR T-cell platform licensed from the University of Pittsburgh.
- In vivo evaluations for GEAR-NK were planned for 2023, and human clinical trials were planned for 2024; these are forward-looking plans and not completed milestones.
- The company expects no significant revenue for at least two years and expects continuing operating losses and negative operating cash flow through at least 2023 or longer.
- Management expects to require additional equity, debt, collaboration or licensing financing. It stated that cash on hand was expected to cover short-term needs into the third quarter of 2023, assuming no strategic transactions were pursued.
- The Statera BioPharma strategic agreement for STAT-201 was terminated by mutual agreement in August 2022.
- The company reduced priority for CPT60621, a Parkinson’s disease product candidate, and was negotiating a potential buyout of its remaining ownership rights.
Debt, Liquidity and Contingencies
- The company has no existing bank credit lines and no definitive source of additional financing disclosed in the filing.
- Under the VyGen arrangements, Coeptis issued promissory notes totaling $3.25 million. The CD38-GEAR-NK note was extended to September 30, 2022; if not timely paid, the filing states that the note would be cancelled and the company’s revenue interest would automatically decline from 50% to 25%. The filing text does not clearly state the final settlement status as of the merger closing.
- The independent auditors’ report included a going-concern explanatory paragraph because additional capital is needed to fund planned activities and ordinary-course obligations.
- The company rents office space for $3,750 per month under a lease ending May 31, 2024.
- Management reported no pending legal proceedings expected to have a material adverse effect, but biotechnology, regulatory, intellectual-property and financing contingencies remain substantial.
Principal Risks
- Substantial doubt regarding the company’s ability to continue as a going concern and dependence on additional financing.
- Minimal revenue, substantial historical losses and no expectation of near-term product revenue or profitability.
- Early-stage product candidates may fail in preclinical or clinical development or may not receive regulatory approval.
- Dependence on third-party collaborators, licensors, contract manufacturers and future commercial partners.
- Limited direct intellectual-property ownership and risk of license loss, infringement claims or inadequate patent protection.
- Potential dilution from future equity financing, equity incentive awards and outstanding warrants.
- Risk of Nasdaq delisting if minimum bid price, equity, liquidity or other continued-listing requirements are not maintained.
- Execution and integration risks following the reverse merger, including the ability to maintain public-company controls and operations.
Investor Verification Checklist
- Verify the final post-closing share count, warrant dilution and terms of all outstanding warrants.
- Review the June 30, 2022 financial statements and pro forma financial statements in Exhibits 99.1 and 99.2 for detailed liabilities, cash flows and going-concern disclosures.
- Confirm the status of the $3.25 million VyGen promissory notes and the company’s retained economic interest in CD38-GEAR-NK.
- Assess available cash, subsequent financing activity and the company’s expected cash runway after October 28, 2022.
- Validate the development status, regulatory pathway, intellectual-property ownership and funding requirements for the CD38 and SNAP-CAR programs.
- Monitor Nasdaq compliance, future equity or debt financings, related-party transactions and potential dilution under the 2022 Equity Incentive Plan.